CMS Has Opportunity To Improve BIPA Process In 2002 Public Meetings
This article was originally published in The Gray Sheet
While CMS' August public meeting on lab test coding and payment was successful, the agency can do more to make its process transparent to the public, Gordon Schatz, an attorney at the law firm Reed Smith, maintained at a Nov. 15 American Association for Clinical Chemistry conference
You may also be interested in...
House and Senate Democrats sponsor legislation to authorize FTC enforcement against sales of "consumer goods and services at an unconscionably excessive price during the" COVID-19 pandemic. "It’s outrageous that some companies and individuals are taking advantage of consumers by price-gouging," says Energy and Commerce Committee Chairman Frank Pallone.
Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.
A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”